A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Esophageal Squamous Cell Carcinoma · Ivonescimab · Neoadjuvant

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tangdu Hospitial, Xi'an, Shannxi, China
Contact: Study coordinator (Xing Li) · tangduec@126.com · +86 02984777551
Contact: Principal Investigator (Xiaolong Yan)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Resectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Tumor Regression Grade As Predictor of Adjuvant Therapy

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)Recruiting

Fuzhou, China

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China